多替阿巴拉米片对艾滋病有多大的疗效？

On January 22, 2018, GlaxoSmithKline (GSK) announced that its single-pill combination preparation (Inbec) with the new generation integrase inhibitor dolutegravir (DTG) as the core for the treatment of HIV was officially launched in mainland China. This is the first single-pill compound preparation with a complete treatment plan in the field of HIV treatment in mainland China. 

How effective is doteabalamid tablets in treating AIDS?

Judging from a large number of clinical trial data, DTG has a low discontinuation rate due to adverse drug reactions (ADR) or virological failure, which are 5.8% and 0.5% respectively. The ADR drops significantly after one year of taking the drug. The most common adverse reactions are gastrointestinal dysfunction, mental disorders and neurological disorders, but the adverse reaction rates are less than 1.5%.

From the comparison with patients who failed the first-line regimen of RAL (Ascent) and EVG (Evitegravir), the other two integrase inhibitors, the number of drug-resistant mutations in dolutea palamid tablets is significantly less than that of the other two drugs, making it less likely to develop drug resistance. In the real world, antiviral treatment-naïve patients treated with DTG have a lower proportion of central nervous system-related (CNS) adverse events than the four drugs RAL (Ascent), DRV/r (darunavir), EFV (efavirenz) and ATV/r (atazanavir). Therefore, the drug safety of Suimeike, which is based on DTG integrase inhibitors, has proven to be controllable. 

In general, Dolutegra abalamib tablets have four main advantages: 1. Excellent efficacy and significant viral suppression effect; 2. The three drugs are equally equivalent, and both newly-treated and previously treated patients have a high resistance barrier, which is not easy to lead to drug resistance; 3. It is easy to take, and only needs to be taken once a day, without considering food effects; 4. The drug has low side effects and good tolerability, and the discontinuation rate due to drug side effects is low; 5. There are few interactions between metabolic pathways and other drugs.

The above is an introduction to the effects of AIDS treatment. I hope it will be helpful to you.